PG
VRTX icon

Proffitt & Goodson’s Vertex Pharmaceuticals VRTX Stock Holding History

Proffitt & Goodson’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.5K Hold
28
– – ﹤0.01% 220
2025
Q4 		$12.7K Sell
28
-32
-53% -$13.8K ﹤0.01% 216
2025
Q3 		$23.5K Buy
+60
New +$25.1K ﹤0.01% 200
2024
Q4 		– Sell
-4
Closed -$1.86K – 315
2024
Q3 		$1.86K Buy
+4
New +$1.92K ﹤0.01% 276

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Proffitt & Goodson's VRTX Position: Q1 2026 in Review

Proffitt & Goodson held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 28 shares worth $12.5K. The position accounts for ﹤0.01% of the portfolio, ranked #220.

Proffitt & Goodson first reported a position in VRTX in Q3 2024 and has held it in 4 quarters since. The position peaked at $23.5K in Q3 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Proffitt & Goodson held 28 shares of Vertex Pharmaceuticals worth $12.5K as of Q1 2026.
  • Proffitt & Goodson left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Proffitt & Goodson's portfolio in Q1 2026, its #220 holding.
  • Proffitt & Goodson first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • Proffitt & Goodson's Vertex Pharmaceuticals position peaked at $23.5K in Q3 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Proffitt & Goodson's 13F filing for Q1 2026, filed 6 May 2026.